Minatx company
Harnessing the innate mechanism of gene activation, MiNA Therapeutics’ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver diseases. Our initial product candidate will achieve clinical proof of concept in 2017.
Total Funding:
£23M
Headquarters:
London, England, United Kingdom
Funding Status:
N/A
Employee Number:
1-10
Estimated Revenue:
$1M to $10M
Investment Stage:
N/A
Last Funding Type:
Series A
Number Of Exists:
Series A
Technology:
P4 Medicine
Investor Type:
Company
Investors Number:
1
Founded Date:
2008
Industry:
Personalized Medicine